FDA Approves Daklinza As New Treatment For Chronic Hepatitis C Genotype 3 Infections
News
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb’s product Daklinza (daclatasvir) for treatment of hepatitis C virus (HCV) genotype 3 infections. Daklinza is the first drug that has ... Read more